TY - JOUR T1 - Anti-Sars-Cov-2 IgA And IgG In Human Milk After Vaccination Is Dependent On Vaccine Type And Previous Sars-Cov-2 Exposure: A Longitudinal Study JF - medRxiv DO - 10.1101/2021.05.20.21257512 SP - 2021.05.20.21257512 AU - Marta Selma-Royo AU - Christine Bäuerl AU - Desirée Mena-Tudela AU - Laia Aguilar-Camprubí AU - Francisco J Pérez-Cano AU - Anna Parra-Llorca AU - Carles Lerin AU - Cecilia Martínez-Costa AU - Maria Carmen Collado AU - on behalf of MilkCORONA study team Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/23/2021.05.20.21257512.abstract N2 - Importance Limited data are available on COVID-19 vaccine impact in lactating women.Objective To evaluate the impact of different COVID-19 vaccines on specific anti-SARS-CoV-2 IgA and IgG levels in human milk.Design, Settings and Participants In this prospective observational study in Spain, 75 lactating women from priority groups receiving vaccination against SARS-CoV-2 were included (January to April 2021). Human milk samples were collected at seven-time points. A group with confirmed SARS-CoV-2 infection (n=19) and a group of women from prepandemic time (n=13) were included.Exposure mRNA vaccines (BNT162b2 and mRNA-1273) and adenovirus-vectored vaccine (ChAdOx1 nCoV-19).Main Outcome(s) and Measure(s) Presence of IgA and IgG against RBD SARS-CoV-2 in breast milk.Results Seventy-five vaccinated lactating women [mean age, 34.9 ± 3.7 years] of whom 96% were Caucasic and 92% were health care workers. A total of 417 milk samples were included and vaccine distribution was BioNTech/Pfizer (BNT162b2, n=30), Moderna (mRNA-1273, n=21), and AstraZeneca (ChAdOx1 nCoV-19, n=24). For each vaccine, 7 time points were collected from baseline up to 25 days after the 1st dose and same points were collected for mRNA vaccines 30 days after 2nd dose. A strong reactivity was observed for IgG and IgA after vaccination mainly after the 2nd dose. Presence and the persistence of specific SARS-CoV-2 antibodies in breast milk were dependent on the vaccine-type and, on previous virus exposure. High inter-variability was observed, being relevant for IgA antibodies. IgG levels were significantly higher than those observed in milk from COVID-19 women while IgA levels were lower. Women with previous COVID-19 increased the IgG levels after the 1st dose to a similar level observed in vaccinated women after the 2nd dose.Conclusions and Relevance Breast milk from vaccinated women contains anti-SARS-CoV-2 IgA and IgG, with highest after the 2nd dose. Levels were dependent on vaccine type and previous exposure to SARS-CoV-2. Previous COVID-19 influenced the vaccine effect after a single dose, which could be especially relevant in the design of vaccination protocols. Further studies are warranted to demonstrate the potential protective role of these antibodies against COVID-19 in infants from vaccinated and infected mothers through breastfeeding.Trial Registration NCT04751734Question What is the effect of the different COVID-19 vaccines on the anti-SARS-CoV-2 antibodies in breast milk? Is the vaccine-specific antibody response in milk comparable to a natural infection? What would be the effect of vaccination on human milk antibodies in women with past SARS-CoV-2 infection?Findings In this prospective, observational and multicenter study in Spain, lactating women within the priority groups receiving the vaccination against SARS-CoV-2 were included. Although there is a high intra- and inter-variability in the generation of specific SARS-CoV-2 antibodies in breast milk, they are also dependent on the vaccine-type and previous viral exposure.Meaning Maternal SARS-CoV-2 vaccination provides anti-SARS-CoV-2 antibodies, both IgA and IgG, in human milk and it depends on vaccines and previous COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04751734Funding Statement-Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures were in accordance with the ethical standards approved by the Ethical Committee of the Hospital Clinico Universitario (Ref. 2020/133), the Institut de Recerca Sant Joan de Deu (Ref. PIC-94-21) and CSIC (Ref. 061/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes- ER -